Collagen may be the darling of the beauty world for its purported antiwrinkle function, but too much of the protein can have ugly—even deadly—consequences. Measuring and treating this overabundance, known as fibrosis, presents a seemingly impossible challenge. Thomas Hayden visits a company in California offering a weighty solution.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
18 January 2011
In the January 2011 issue of Nature Medicine, the article entitled “Scarred by disease” (Nat. Med. 17, 18–20, 2011) stated that the STX-100 compound from Stromedix is a small-molecule drug. However, the drug is actually a monoclonal antibody. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hayden, T. Scarred by disease. Nat Med 17, 18–20 (2011). https://doi.org/10.1038/nm0111-18
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0111-18
This article is cited by
-
Corrections
Nature Medicine (2011)
